Enosis & OVID Clinics partner to combine VR & psychedelics for in-clinic psychotherapy

In Virtual Reality News

November 2, 2022 – Enosis Therapeutics, a medical technology and psychedelic research company that leverages virtual reality (VR) for the contextual modulation of psychedelic therapy to improve treatment outcomes, has partnered with OVID Clinics and the MIND Foundation to implement an in-clinic application of VR with Psychedelic-Assisted therapy.

OVID Clinics, a Berlin-based healthcare services provider that delivers integration-focused and psychedelic-based psychotherapies through its network of clinics, has begun offering its patients the opportunity to receive psychedelic-assisted psychotherapy integrated with Enosis’ virtual technology protocols.

In June 2022, Enosis collaborated with the Swinburne University of Technology in Australia and announced positive results from its study on the synergistic application of VR in psychedelics. The preliminary results showed that Enosis’ VR scenarios, combined with a guided psychedelic experience, generated high levels of acceptance and satisfaction. Enosis stated that the positive results from this first study have led the company to begin offering VR scenarios with psychedelic-assisted therapy inside OVID Clinics.

“The Enosis team is honored to partner with OVID Clinics and the MIND Foundation to commence the first in-clinic application of our VR protocols as an adjunct to psychedelic-assisted psychotherapy,” said Agnieszka D. Sekula, Co-Founder of Enosis Therapeutics. “Enhancing patient accessibility to our VR experiences remains our top priority and we are excited to bring this novel treatment to patients in need. Together with the OVID team, our focus is to achieve positive patient outcomes and longer-lasting therapeutic benefits for patients battling mental health illnesses.”

Beyond offering the in-clinic protocol in Berlin, Enosis and OVID will be gathering data for a research collaboration aiming to investigate the synergistic effects of psychedelic and digital interventions in the hopes that the results demonstrate better therapeutic patient outcomes and enhance overall patient wellbeing.

“At OVID Clinics, we believe in a personalized, evidence-based, medical & psychotherapeutic approach tailored to the patients’ needs. We recognize the value of Enosis´ VR technologies in the integration process following psychedelic therapy,” said Sergio Pérez Rosal, Co-Founder and Chief Executive Officer of OVID Clinics. “We are convinced that this partnership will help innovate the field by shifting the focus from the psychedelic substance to the psychedelic experience and its integration, supporting patients in every step of the way through their journey into well-being.”

Enosis stated that its partnership with OVID will help to further demonstrate the power of VR as a tool for enhancing mental health and highlights that VR’s capabilities and protocols are gaining increased momentum in psychedelics research and clinical settings. Patient enrollment is in progress now.

To learn more about Enosis and its work to catalyze the mainstream adoption of psychedelic treatment with VR, please visit the company’s website.

Image / video credit: Enosis / YouTube

About the author

Sam Sprigg

Sam is the Founder and Managing Editor of Auganix. With a background in research and report writing, he has been covering XR industry news for the past five years.